Steatohepatitis/Metabolic Liver Disease News

PARIS — In this exclusive interview from the International Liver Congress 2018, Mani Subramanian, PhD, provides an update on Gilead’s ongoing clinical trials for the treatment of advanced fibrosis in patients with nonalcoholic steatohepatitis.

PARIS — Patients with obesity and nonalcoholic fatty liver disease who underwent assisted weightloss with an intragastric balloon showed no clinically significant alterations in gut microflora or associated metabonomics, according to a presentation at the International Liver Congress 2018.

PARIS — Givosiran, an investigational RNA interference therapeutic, was generally well-tolerated and reduced aminolevulinic acid and porphobilinogen accumulation in patients with acute hepatic porphyrias and ameliorate disease manifestations, according to a presentation at the International Liver Congress 2018.

PARIS — Patients who received NGM282, a novel growth factor, showed improved noninvasive markers of nonalcoholic steatohepatitis and a histologic response after 12 weeks of dosing, according to a presenter at the International Liver Congress 2018.

PARIS — GR-MD-02, a novel galectin-3 protein, did not improve hepatic venous pressure gradient in patients with nonalcoholic steatohepatitis and cirrhosis; however, the inhibitor did significantly improve hepatocyte ballooning, according to a presentation at the International Liver Congress 2018.

PARIS — A web-based lifestyle counselling program for patients with nonalcoholic fatty liver disease demonstrated long-term efficacy and non-inferiority compared with group-based lifestyle counselling, according to a presentation at the International Liver Congress 2018.

PARIS — Twelve weeks of MGL-3196 — an orally active, highly selective thyroid hormone receptor beta-selective agonist — significantly decreased hepatic fat in patients with nonalcoholic steatohepatitis compared with placebo in a phase 2 trial, according to data presented at the International Liver Congress 2018.

PARIS — Food insecurity correlated with an increased risk for advanced fibrosis, particularly among patients with diabetes, according to a presentation at the International Liver Congress 2018.

PARIS — All-cause hospitalizations, rate of emergency visits and inpatient costs increased by more than 90% following compensated cirrhosis diagnosis among patients with nonalcoholic fatty liver disease or nonalcoholic steatohepatitis, according to a presentation at the International Liver Congress 2018.

PARIS — Cenicriviroc, an oral C-C chemokine receptor type 2 and type 5 antagonist also known as CVC, was well-tolerated and provided antifibrotic activity in adult patients with nonalcoholic steatohepatitis and fibrosis in a phase 2b clinical study, according to data presented at the International Liver Congress 2018.